The estimated Net Worth of Dean J Mitchell is at least $4.12 Milión dollars as of 9 March 2024. Mr. Mitchell owns over 106,837 units of Theravance Biopharma Inc stock worth over $3,755,751 and over the last 18 years he sold TBPH stock worth over $0. In addition, he makes $359,879 as Independent Director at Theravance Biopharma Inc.
Dean has made over 19 trades of the Theravance Biopharma Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 106,837 units of TBPH stock worth $865,380 on 9 March 2024.
The largest trade he's ever made was exercising 106,837 units of Theravance Biopharma Inc stock on 9 March 2024 worth over $865,380. On average, Dean trades about 4,799 units every 54 days since 2006. As of 9 March 2024 he still owns at least 463,673 units of Theravance Biopharma Inc stock.
You can see the complete history of Mr. Mitchell stock trades at the bottom of the page.
Dean Jonathan Mitchell serves as Independent Director of the Company. Mr. Mitchell has served as Executive Chairman of the board of directors of Covis Pharma Holdings, a specialty pharmaceutical company, since August 2013. He was Chairman of PaxVax Corporation from January 2016 until its sale in October 2018 and is on the board of directors ImmunoGen Inc. since 2012 and Intrexon, Inc. since 2009. Mr. Mitchell served as President and Chief Executive Officer of Lux Biosciences, Inc., a biotechnology company focusing on the treatment of ophthalmic diseases, from July 2010 to August 2013. Prior to Lux Biosciences, he served as President and Chief Executive Officer of both Alpharma, Inc., a publicly traded specialty pharmaceutical company, from 2006 until its acquisition by King Pharmaceuticals, Inc. in 2008, and Guilford Pharmaceuticals, Inc., a publicly traded pharmaceutical company focused in oncology and acute care, from 2004 until its acquisition by MGI Pharma Inc. in 2005. From 2001 to 2004 he served in\ various senior executive capacities in the worldwide medicines group of Bristol-Myers Squibb Company, a pharmaceutical company. Prior to the Bristol-Myers Squibb Company, he spent 14 years at GlaxoSmithKline plc, in assignments of increasing responsibility spanning sales, marketing, general management, commercial strategy and clinical development and product strategy. Mr. Mitchell holds an M.B.A. from City University London and a B.Sc. in biology from Coventry University.
As the Independent Director of Theravance Biopharma Inc, the total compensation of Dean Mitchell at Theravance Biopharma Inc is $359,879. There are 13 executives at Theravance Biopharma Inc getting paid more, with Rick Winningham having the highest compensation of $5,932,410.
Dean Mitchell is 64, he's been the Independent Director of Theravance Biopharma Inc since 2014. There are 7 older and 19 younger executives at Theravance Biopharma Inc. The oldest executive at Theravance Biopharma Inc is Burton Malkiel, 87, who is the Independent Director.
Dean's mailing address filed with the SEC is C/O PRAXIS PRECISION MEDICINES, INC., 99 HIGH STREET, 30TH FLOOR, BOSTON, MA, 02110.
Over the last 11 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva, a Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.
theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Theravance Biopharma Inc executives and other stock owners filed with the SEC include: